

Susana Vives Polo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8242677/publications.pdf>

Version: 2024-02-01

37
papers

516
citations

759055

12
h-index

713332

21
g-index

40
all docs

40
docs citations

40
times ranked

550
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 1519-1531. | 13.9 | 186 |
| 2 | Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, e294-e297. | 1.7 | 29 |
| 3 | Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , 2022, 6, 1278-1295. | 2.5 | 29 |
| 4 | European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. <i>Blood Advances</i> , 2022, 6, 1193-1206. | 2.5 | 26 |
| 5 | Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. <i>Blood Advances</i> , 2021, 5, 760-770. | 2.5 | 18 |
| 6 | A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2003-2014. | 2.0 | 16 |
| 7 | A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019, 76, 1-10. | 0.4 | 15 |
| 8 | Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019, 102, 79-86. | 1.1 | 14 |
| 9 | Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. <i>Cytotherapy</i> , 2014, 16, 406-411. | 0.3 | 13 |
| 10 | Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. <i>Cancer</i> , 2019, 125, 2810-2817. | 2.0 | 13 |
| 11 | A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329. | 1.3 | 13 |
| 12 | Efficacy and safety of native versus pegylated <i>Escherichia coli</i> asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1634-1643. | 0.6 | 13 |
| 13 | Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. <i>Cancers</i> , 2022, 14, 1734. | 1.7 | 13 |
| 14 | Acute myeloid leukemia with <i>inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2)</i> : Study of 61 patients treated with intensive protocols. <i>European Journal of Haematology</i> , 2020, 105, 138-147. | 1.1 | 12 |
| 15 | Evolving treatment patterns and outcomes in older patients (>60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021, 35, 1571-1585. | 3.3 | 12 |
| 16 | Adverse prognostic impact of complex karyotype (>3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia Research</i> , 2021, 109, 106612. | 0.4 | 11 |
| 17 | A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. <i>Blood Cancer Journal</i> , 2020, 10, 43. | 2.8 | 10 |
| 18 | Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. <i>Journal of Clinical Apheresis</i> , 2012, 27, 260-262. | 0.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2018, 68, 79-84. | 0.4 | 9 |
| 20 | A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1497-1508. | 0.8 | 7 |
| 21 | The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , 2021, 13, 2458. | 1.7 | 7 |
| 22 | Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older. <i>European Journal of Haematology</i> , 2015, 95, 576-582. | 1.1 | 6 |
| 23 | Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 815-819. | 1.5 | 6 |
| 24 | The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019, 186, 263-268. | 1.2 | 6 |
| 25 | Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 916-922. | 0.6 | 5 |
| 26 | Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. <i>Cancers</i> , 2022, 14, 2342. | 1.7 | 4 |
| 27 | DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019016. | 0.5 | 3 |
| 28 | Avances en el tratamiento de la leucemia aguda linfoblástica del adulto. <i>Medicina Clínica</i> , 2017, 149, 119-121. | 0.3 | 2 |
| 29 | Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML. <i>Genes</i> , 2020, 11, 73. | 1.0 | 2 |
| 30 | Impact of previous admission to an intensive care unit on stem cell transplantation outcome. <i>Medicina Clínica</i> , 2020, 155, 382-387. | 0.3 | 1 |
| 31 | Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. <i>Medicina Clínica</i> , 2021, , . | 0.3 | 1 |
| 32 | Gemtuzumab ozogamicina a bajas dosis en adultos con leucemia mieloide aguda. <i>Medicina Clínica</i> , 2021, 157, 325-328. | 0.3 | 1 |
| 33 | Blinatumomab for treating acute lymphoblastic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 477-485. | 0.5 | 0 |
| 34 | Segundas neoplasias en pacientes adultos receptores de un trasplante de progenitores hematopoyéticos. <i>Medicina Clínica</i> , 2018, 150, 421-427. | 0.3 | 0 |
| 35 | Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. <i>Leukemia Research</i> , 2021, 101, 106492. | 0.4 | 0 |
| 36 | Debut de leucemia aguda mieloblástica con hemorragias retinianas bilaterales. <i>Medicina Clínica</i> , 2021, 158, 98-98. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Neoplasia de células dendríticas blásticas plasmacitoides. Estudio de tres casos. Medicina Clínica, 2020, 154, 524-525. | 0.3 | 0 |